胡大一教授谈“孙杨服用曲美他嗪事件”

2014-11-26 译名 国际循环

2014年11月25日体育总局反兴奋剂中心在其官方网站公布:孙杨在5月17日尿检中被查出使用违禁药物曲美他嗪,遭禁赛3个月等处罚。该事件引发众多媒体的报道和网络热议。 为从医学专业角度更好的了解本次事件中涉及的药物及相关医学背景,我们特采访了北京大学人民医院著名心血管专家胡大一教授。胡教授从以下二方面解读了本次事件: 1.运动员是否能使用曲美他嗪? 曲美他嗪是心内科常用药物,主要用于

2014年11月25日体育总局反兴奋剂中心在其官方网站公布:孙杨在5月17日尿检中被查出使用违禁药物曲美他嗪,遭禁赛3个月等处罚。该事件引发众多媒体的报道和网络热议。

为从医学专业角度更好的了解本次事件中涉及的药物及相关医学背景,我们特采访了北京大学人民医院著名心血管专家胡大一教授。胡教授从以下二方面解读了本次事件:

1.运动员是否能使用曲美他嗪?


曲美他嗪是心内科常用药物,主要用于冠心病的治疗。今年1月份曲美他嗪因其潜在的增加运动能力的作用,被世界反兴奋剂/违禁药品组织列为赛内违禁药物。作为处方药物其使用应在专业医生的处方和指导下进行。该药物说明书已包含“运动员慎用”内容。根据病情,运动员也可以处方曲美他嗪,但胡大一教授指出:“运动员很多药物在比赛期间是不能使用的,医生应了解和注意。”

2.曲美他嗪被列为运动员违禁药,对冠心病患者用药有何影响?

曲美他嗪的作用机制和一般理解的“兴奋剂”不同,它没有中枢神经兴奋作用。曲美他嗪通过优化心肌能量代谢,提高机体对氧的利用效率,以产生更多的能量供应。“早年我主持的一项研究证实,曲美他嗪能很好地控制心肌缺血,改善心绞痛发作,”胡大一教授说,“国内外有许多类似的研究也得到了同样的结果”。

近年研究显示在作用于缺血心肌的同时,曲美他嗪对骨骼肌也有潜在的代谢改善作用,从心脏和骨骼肌两个方面提高患者的运动耐量。运动耐量的提高可以有助于患者改善生活质量,恢复社会功能,甚至改善预后。

胡大一教授最后总结说:“对于有症状的冠心病患者,医生处方曲美他嗪是合理的,而且该药的安全性良好,患者无需担心。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769450, encodeId=f8ae1e694504f, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e67738065109, createdName=jianjun79, createdTime=Sat Dec 20 19:11:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12861, encodeId=5fb5128615b, content=没有说出什么新意,只是为了出头露面吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.228.26.13, createdTime=Sun Nov 30 08:46:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394787, encodeId=d31f1394e87c8, content=<a href='/topic/show?id=94bb83e90b7' target=_blank style='color:#2F92EE;'>#胡大一#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83790, encryptionId=94bb83e90b7, topicName=胡大一)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Nov 28 13:11:00 CST 2014, time=2014-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12691, encodeId=630f12691f6, content=专业人说专业事,有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=118.244.255.149, createdTime=Wed Nov 26 22:34:00 CST 2014, time=2014-11-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769450, encodeId=f8ae1e694504f, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e67738065109, createdName=jianjun79, createdTime=Sat Dec 20 19:11:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12861, encodeId=5fb5128615b, content=没有说出什么新意,只是为了出头露面吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.228.26.13, createdTime=Sun Nov 30 08:46:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394787, encodeId=d31f1394e87c8, content=<a href='/topic/show?id=94bb83e90b7' target=_blank style='color:#2F92EE;'>#胡大一#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83790, encryptionId=94bb83e90b7, topicName=胡大一)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Nov 28 13:11:00 CST 2014, time=2014-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12691, encodeId=630f12691f6, content=专业人说专业事,有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=118.244.255.149, createdTime=Wed Nov 26 22:34:00 CST 2014, time=2014-11-26, status=1, ipAttribution=)]
    2014-11-30 101.228.26.13

    没有说出什么新意,只是为了出头露面吧!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1769450, encodeId=f8ae1e694504f, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e67738065109, createdName=jianjun79, createdTime=Sat Dec 20 19:11:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12861, encodeId=5fb5128615b, content=没有说出什么新意,只是为了出头露面吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.228.26.13, createdTime=Sun Nov 30 08:46:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394787, encodeId=d31f1394e87c8, content=<a href='/topic/show?id=94bb83e90b7' target=_blank style='color:#2F92EE;'>#胡大一#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83790, encryptionId=94bb83e90b7, topicName=胡大一)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Nov 28 13:11:00 CST 2014, time=2014-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12691, encodeId=630f12691f6, content=专业人说专业事,有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=118.244.255.149, createdTime=Wed Nov 26 22:34:00 CST 2014, time=2014-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769450, encodeId=f8ae1e694504f, content=<a href='/topic/show?id=257f602491f' target=_blank style='color:#2F92EE;'>#曲美他嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60249, encryptionId=257f602491f, topicName=曲美他嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e67738065109, createdName=jianjun79, createdTime=Sat Dec 20 19:11:00 CST 2014, time=2014-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12861, encodeId=5fb5128615b, content=没有说出什么新意,只是为了出头露面吧!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=101.228.26.13, createdTime=Sun Nov 30 08:46:00 CST 2014, time=2014-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394787, encodeId=d31f1394e87c8, content=<a href='/topic/show?id=94bb83e90b7' target=_blank style='color:#2F92EE;'>#胡大一#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83790, encryptionId=94bb83e90b7, topicName=胡大一)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Fri Nov 28 13:11:00 CST 2014, time=2014-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12691, encodeId=630f12691f6, content=专业人说专业事,有道理, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=118.244.255.149, createdTime=Wed Nov 26 22:34:00 CST 2014, time=2014-11-26, status=1, ipAttribution=)]
    2014-11-26 118.244.255.149

    专业人说专业事,有道理

    0

相关资讯

CFDA:关注曲美他嗪引起运动障碍等安全性风险

曲美他嗪于2000年在我国上市,目前有片剂(20 mg)和缓释片剂(35 mg)两种剂型。曲美他嗪属于心血管系统药物,临床用于心绞痛发作的预防性治疗和眩晕、耳鸣的辅助性对症治疗。近期,欧盟药品管理局(EMA)发布消息,建议限制曲美他嗪的使用,并警惕其引起的运动功能障碍等安全性风险。根据国家药品不良反应监测系统数据库信息分析情况及欧盟评估结果,国家食品药品监督管理总局于4日在其官方网站上发布信息

CFDA要求修订盐酸曲美他嗪说明书

为适应科学用药需要,保障公众用药安全,国家食品药品监督管理总局(CFDA)近日决定对盐酸曲美他嗪片及盐酸曲美他嗪胶囊说明书进行修订,修订内容涉及【适应证】、【用法用量】、【不良反应】、【禁忌】、【注意事项】、【孕妇及哺乳期妇女用药】、【儿童用药】、【老年用药】、【药物相互作用】、【药物过量】、【临床试验】、【药理毒理】和【药代动力学】项下相关内容(详见附件)。通知内容如下: 一、在2